March 26, 2021 PR/Corporate

Roche receives positive CHMP opinion for Tecentriq as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancer

Recommendation is based on the Phase III IMpower110 study showing that Tecentriq significantly improved overall survival in people with high PD-L1 expression, compared with chemotherapy If approved, Tecentriq could offer people with a specific type of lung cancer a chemotherapy-free option in the first-line treatment setting Basel, 26 March 2021 – Roche (SIX: RO, ROG;... Read more

March 23, 2021 Product Launch

Roche launches new high throughput configurations for cobas pro integrated solutions to increase testing efficiency

With eight new configurations, cobas pro® integrated solutions offers labs greater flexibility to ramp up their testing capacity to adapt to evolving testing needs This will allow a greater number of patient samples to be processed faster By consolidating up to four analytical units on a single platform, testing efficiency in high-volume labs is increased... Read more

March 23, 2021 Bio/Pharma/CRO Clinical Research/Diagn. PAI Top-10 Product Launch

New phase III data shows investigational antibody cocktail casirivimab and imdevimab reduced hospitalisation or death by 70% in non-hospitalised patients with COVID-19

Investigational antibody cocktail of casirivimab and imdevimab also significantly shortened the duration of symptoms by four days The 2,400 mg and 1,200 mg doses tested in the phase III study had similar efficacy across all endpoints Companion dose-ranging phase II trial showed significant and comparable viral reductions for a range of doses of casirivimab and... Read more

March 22, 2021 Uncategorized

Roche provides update on tominersen programme in manifest Huntington’s disease

Dosing to stop in Phase III clinical study of tominersen following recommendation from an Independent Data Monitoring Committee (iDMC) No new safety signals were identified for tominersen in the iDMC’s review              Basel, 22 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the decision to discontinue dosing in the Phase III GENERATION HD1... Read more

March 22, 2021 Bio/Pharma/CRO

Pivotal Phase III study shows Roche’s Tecentriq helped people with early lung cancer live longer without their disease returning

First Phase III study to show that a cancer immunotherapy improves disease-free survival in people with resectable early stage lung cancer compared to best supportive care Treating lung cancer early, before it has spread, may help prevent the disease from returning and therefore provide the best opportunity for a cure Data will be submitted to... Read more

March 17, 2021 Product Launch

Roche launches cobas pure integrated solutions analyser to help simplify operations in small to medium sized labs

cobas® pure integrated solutions brings together three diagnostic technologies1 on a single platform to optimise space and resources in small to medium laboratory settings With a footprint of just two square meters, this new analyser provides small to medium sized labs with access to more than 230 diagnostic tests2 across a wide-range of disease areas... Read more

March 16, 2021 PAI Top-10

Roche Annual General Meeting 2021

All proposals of the Board of Directors approved Christoph Franz re-elected as Chairman of the Board of Directors; all current Board members re-elected 34th consecutive dividend increase to CHF 9.10 per share Basel, 16 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that its shareholders approved all proposals of the Board of... Read more

March 16, 2021 Liq. Handling & Robotics Product Launch

Roche launches SARS-CoV-2 variant test to help monitor emerging coronavirus mutations

The cobas SARS-CoV-2 Variant Set 1 Test is designed to detect key spike mutations in virus variants associated with increased human-to-human transmission Accurate detection and differentiation of SARS-CoV-2 mutations can help assess the spread of circulating variants and monitor their potential impact on therapeutics, vaccines and public health interventions Periodic assessments against emerging variants have... Read more

March 15, 2021 Clinical Research/Diagn. Liq. Handling & Robotics M&A, Partnerships

Roche signs definitive merger agreement with GenMark Diagnostics, Inc., to access novel technology to test for broad range of pathogens with one patient sample

Basel, 15 March 2021 Roche to acquire GenMark Diagnostics for US$ 24.05 per share with the expectation to close in the 2nd quarter of 2021 GenMark provides molecular diagnostic tests that are designed to detect multiple pathogens from a single patient sample GenMark’s ePlex platform delivers rapid and actionable results so clinicians can determine the... Read more